SOMAÍ Pharmaceuticals has partnered with Georgelle Pharmaceutical Ltd. to bring a wide range of cannabis-based medicines to Irish patients, marking its fifth international expansion this year. The partnership aims to increase access to cannabis-based treatments in Ireland, where patients have had limited options previously.
The Victorian government is reviewing its approach to medicinal cannabis use in workplaces due to concerns about the reliability and nuance of current drug testing methods. Medicinal cannabis use has increased since it was legalized in Australia in 2016, leading to complications for users in safety-sensitive industries and roadside drug testing. While drug testing aims to ensure safety, experts highlight limitations in detecting impairment and the potential for false positives, especially with oral fluid tests. The debate centers on balancing occupational health and safety with the rights of medicinal cannabis users. The AFPA acknowledges limitations in testing, emphasizing the need for more robust methods to determine impairment. The parliament is considering a more nuanced approach, treating cannabis similarly to other prescription drugs and relying on the patient-doctor relationship to assess safety.
